

Bjarne R Bartlett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1714836/publications.pdf>

Version: 2024-02-01

23
papers

17,377
citations

687363
13
h-index

940533
16
g-index

24
all docs

24
docs citations

24
times ranked

24603
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	27.0	7,696
2	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	12.6	4,945
3	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
4	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science, 2019, 364, 485-491.	12.6	395
5	The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. Clinical Cancer Research, 2017, 23, 2471-2477.	7.0	154
6	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. Clinical Cancer Research, 2019, 25, 7024-7034.	7.0	104
7	Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies. , 2014, , .		83
8	DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES. Neuro-Oncology, 2014, 16, iii7-iii7.	1.2	50
9	Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	1.6	50
10	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clinical Cancer Research, 2019, 25, 5250-5259.	7.0	46
11	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
12	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.. Journal of Clinical Oncology, 2016, 34, 195-195.	1.6	39
13	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. Cancer Immunology Research, 2019, 7, 1574-1579.	3.4	33
14	PD-1 blockade in tumors with mismatch repair deficiency.. Journal of Clinical Oncology, 2015, 33, LBA100-LBA100.	1.6	31
15	Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.. Journal of Clinical Oncology, 2016, 34, 3003-3003.	1.6	24
16	Digital technology helps remove gender bias in academia. Scientometrics, 2021, 126, 4073-4081.	3.0	11
17	The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF- β 2 as a Companion Target for Checkpoint Blockade Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 754507.	3.7	3
18	Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer.. Journal of Clinical Oncology, 2015, 33, 11025-11025.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Abstract 3957: Optimized plasma collection procedures for liquid biopsy analyses in cancer. , 2016, , .		0
20	Abstract 4058: The miRNA expression profile of inflammatory tumors reveals a unique immune cell profile and potential companion targets for checkpoint blockade immunotherapy. , 2019, , .		0
21	Development of a RNA-Seq based prognostic signature for colon cancer. International Journal of Computational Biology and Drug Design, 2020, 13, 488.	0.3	0
22	Development of a RNA-Seq based prognostic signature for colon cancer. International Journal of Computational Biology and Drug Design, 2020, 13, 488.	0.3	0
23	Abstract 4058: The miRNA expression profile of inflammatory tumors reveals a unique immune cell profile and potential companion targets for checkpoint blockade immunotherapy. , 2019, , .		0